(April 8, 2024, 11:22 AM EDT) -- WASHINGTON, D.C. — The Federal Circuit U.S. Court of Appeals on April 5 said an appeal of a final written decision (FWD) by the Patent Trial and Appeal Board that declared obvious a patented lurasidone dosing regimen is mooted by the expiration of the patent and representations by counsel that an appellant no longer has an interest in exercising its right to exclude, including by seeking damages for pre-expiration infringement....